Antipsychotics in individuals with intellectual disability

The Lancet

Volumn 371, Issue 9623, 2008, Pages 1501-1502

  Gainotti, Sabina ^a   Galeotti, Francesca ^a   Izzicupo, Fabio ^b   Petrini, Carlo ^a   Raschetti, Roberto ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

AGGRESSION; ALZHEIMER DISEASE; BEHAVIOR DISORDER; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFORMED CONSENT; INTELLECTUAL IMPAIRMENT; LETTER; MEDICAL DECISION MAKING; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; ADULT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; ITALY; NOTE; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; DECISION MAKING; HUMANS; INFORMED CONSENT; ITALY; PSYCHOLOGICAL TESTS;

EID: 43049116913     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60648-0     Document Type: Letter

References (3)

1. P Tyrer PC Oliver-Africano Z Ahmed Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial Lancet 371 2008 57 63
2. GA Sachs Position statement: informed consent for research on human subjects with dementia 2007 American Geriatrics Society New York http://www.americangeriatrics.org/products/positionpapers/infconsent.shtml (accessed Jan 18, 2008).
3. PS Appelbaum Assessment of patients' competence to consent to treatment N Engl J Med 357 2007 1834 1840